220 related articles for article (PubMed ID: 30044693)
21. The prognostic value of IKZF1
Kicinski M; Arfeuille C; Grardel N; Bakkus M; Caye-Eude A; Plat G; Ferster A; Uyttebroeck A; De Moerloose B; Rohrlich P; Suciu S; Bertrand Y; Cavé H
Pediatr Blood Cancer; 2023 Jun; 70(6):e30313. PubMed ID: 36971444
[TBL] [Abstract][Full Text] [Related]
22. Aberrant IKZF1 gene as relapse predictor in standard-risk pediatric patients with B-cell precursor acute lymphoblastic leukaemia.
Vshyukova VS; Krasko OV; Yanchanka DA; Meleshko AN
Int J Lab Hematol; 2022 Aug; 44(4):769-776. PubMed ID: 35505470
[TBL] [Abstract][Full Text] [Related]
23. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
24. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
Boer JM; van der Veer A; Rizopoulos D; Fiocco M; Sonneveld E; de Groot-Kruseman HA; Kuiper RP; Hoogerbrugge P; Horstmann M; Zaliova M; Palmi C; Trka J; Fronkova E; Emerenciano M; do Socorro Pombo-de-Oliveira M; Mlynarski W; Szczepanski T; Nebral K; Attarbaschi A; Venn N; Sutton R; Schwab CJ; Enshaei A; Vora A; Stanulla M; Schrappe M; Cazzaniga G; Conter V; Zimmermann M; Moorman AV; Pieters R; den Boer ML
Leukemia; 2016 Jan; 30(1):32-8. PubMed ID: 26202931
[TBL] [Abstract][Full Text] [Related]
25. Loss-of-function but not dominant-negative intragenic
Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
[TBL] [Abstract][Full Text] [Related]
26. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
Vitanza NA; Zaky W; Blum R; Meyer JA; Wang J; Bhatla T; Morrison DJ; Raetz EA; Carroll WL
Pediatr Blood Cancer; 2014 Oct; 61(10):1779-85. PubMed ID: 24976218
[TBL] [Abstract][Full Text] [Related]
27. Improved Outcome for ALL by Prolonging Therapy for
Pieters R; de Groot-Kruseman H; Fiocco M; Verwer F; Van Overveld M; Sonneveld E; van der Velden V; Beverloo HB; Bierings M; Dors N; de Haas V; Hoogerbrugge P; Van der Sluis I; Tissing W; Veening M; Boer J; Den Boer M
J Clin Oncol; 2023 Sep; 41(25):4130-4142. PubMed ID: 37459571
[TBL] [Abstract][Full Text] [Related]
28. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.
Asai D; Imamura T; Suenobu S; Saito A; Hasegawa D; Deguchi T; Hashii Y; Matsumoto K; Kawasaki H; Hori H; Iguchi A; Kosaka Y; Kato K; Horibe K; Yumura-Yagi K; Hara J; Oda M;
Cancer Med; 2013 Jun; 2(3):412-9. PubMed ID: 23930217
[TBL] [Abstract][Full Text] [Related]
29. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
[TBL] [Abstract][Full Text] [Related]
30. IKZF1
Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
[TBL] [Abstract][Full Text] [Related]
31. Successful toxicity reduction during delayed intensification in the non-high-risk arm of Malaysia-Singapore Acute Lymphoblastic Leukaemia 2010 study.
Oh BLZ; Lee SHR; Foo KM; Chiew KH; Seeto ZZL; Chen ZW; Neoh CCC; Liew GSM; Eng JJ; Lam JCM; Chan YH; Quah TC; Tan AM; Yeoh AEJ
Eur J Cancer; 2021 Jan; 142():92-101. PubMed ID: 33246161
[TBL] [Abstract][Full Text] [Related]
32. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
33. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia.
Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698
[TBL] [Abstract][Full Text] [Related]
34. COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia.
Lopes BA; Meyer C; Barbosa TC; Zur Stadt U; Horstmann M; Venn NC; Heatley S; White DL; Sutton R; Pombo-de-Oliveira MS; Marschalek R; Emerenciano M
Oncotarget; 2016 Aug; 7(33):53064-53073. PubMed ID: 27419633
[TBL] [Abstract][Full Text] [Related]
35. Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.
Dong Y; Liu F; Wu C; Li S; Zhao X; Zhang P; Jiao J; Yu X; Ji Y; Zhang M
Clin Exp Immunol; 2016 Sep; 185(3):320-31. PubMed ID: 27198500
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.
Tang B; Cai Z; Wang Z; Lin D; He X; Li Q; Liang X; Huang K; Zhou X; Lin R; Xu N; Fan Z; Huang F; Sun J; Liu X; Liu Q; Zhou H
Bone Marrow Transplant; 2022 Dec; 57(12):1751-1757. PubMed ID: 36056210
[TBL] [Abstract][Full Text] [Related]
37. IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.
Ruiz-Delgado GJ; Cantero-Fortiz Y; León-Peña AA; León-González M; Nuñez-Cortés AK; Ruiz-Argüelles GJ
Rev Invest Clin; 2016; 68(4):210-4. PubMed ID: 27623040
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel.
Aoe M; Ishida H; Matsubara T; Karakawa S; Kawaguchi H; Fujiwara K; Kanamitsu K; Washio K; Okada K; Shibakura M; Shimada A
Int J Lab Hematol; 2018 Aug; 40(4):427-436. PubMed ID: 29575541
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis.
Zhang W; Kuang P; Li H; Wang F; Wang Y
Ann Hematol; 2017 Feb; 96(2):215-225. PubMed ID: 27815723
[TBL] [Abstract][Full Text] [Related]
40. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
Kuiper RP; Waanders E; van der Velden VH; van Reijmersdal SV; Venkatachalam R; Scheijen B; Sonneveld E; van Dongen JJ; Veerman AJ; van Leeuwen FN; van Kessel AG; Hoogerbrugge PM
Leukemia; 2010 Jul; 24(7):1258-64. PubMed ID: 20445578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
